Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
Authors
Keywords
COVID-19, SARS-CoV-2, Antibodies, Nanobodies, Camelide, Bovine, Variants, Vaccines, Omicron
Journal
International Journal of Surgery
Volume 98, Issue -, Pages 106233
Publisher
Elsevier BV
Online
2022-01-20
DOI
10.1016/j.ijsu.2022.106233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
- (2021) Paul-Albert Koenig et al. SCIENCE
- Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)
- (2021) Salma Bessalah et al. 3 Biotech
- Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
- (2021) Zhuoming Liu et al. Cell Host & Microbe
- Immunogenicity and humanization of single‐domain antibodies
- (2021) Martin A. Rossotti et al. FEBS Journal
- Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
- (2021) Huan Ma et al. JOURNAL OF VIROLOGY
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
- (2021) Hebang Yao et al. PLoS Pathogens
- Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
- (2021) Qizhong Lu et al. JOURNAL OF NANOBIOTECHNOLOGY
- Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2
- (2021) Lotfi Chouchane et al. JCI Insight
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Novel SARS-CoV-2 variants: the pandemics within the pandemic
- (2021) Erik Boehm et al. CLINICAL MICROBIOLOGY AND INFECTION
- Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries
- (2021) Rui Wang et al. GENOMICS
- Preparing for the Future — Nanobodies for Covid-19?
- (2021) Ram Sasisekharan NEW ENGLAND JOURNAL OF MEDICINE
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants
- (2021) Ezgi Hacisuleyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19
- (2021) Rohitash Yadav et al. Cells
- An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
- (2021) Cielo García-Montero et al. Vaccines
- COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
- (2021) Muge Cevik et al. CELL
- Neutralizing antibodies for the prevention and treatment of COVID-19
- (2021) Lanying Du et al. Cellular & Molecular Immunology
- The contribution of bovines to human health against viral infections
- (2021) AbdulRahman A. Saied et al. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
- Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
- (2021) Xue Li et al. INFECTION GENETICS AND EVOLUTION
- Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction
- (2021) Satoshi Oshiro et al. INTERNATIONAL DAIRY JOURNAL
- Broad sarbecovirus neutralization by a human monoclonal antibody
- (2021) M. Alejandra Tortorici et al. NATURE
- Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
- (2021) Jianliang Xu et al. NATURE
- SARS-CoV-2 Variants and Vaccines
- (2021) Philip R. Krause et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
- (2021) Emanuele Andreano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
- (2021) Daniele Focosi et al. Viruses-Basel
- Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
- (2021) Zhuoming Liu et al. Human Vaccines & Immunotherapeutics
- Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
- (2021) Khan Sharun et al. Human Vaccines & Immunotherapeutics
- Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies
- (2021) Chengchao Ding et al. Frontiers in Immunology
- Egypt's COVID-19 Recent Happenings and Perspectives: A Mini-Review
- (2021) AbdulRahman A. Saied et al. Frontiers in Public Health
- Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view
- (2021) Ali Najmeddin et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Recent advances in management of COVID-19: A review
- (2021) Soraya Mouffak et al. BIOMEDICINE & PHARMACOTHERAPY
- Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections
- (2021) Timothy Farinholt et al. BMC Medicine
- Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
- (2021) Salim S Abdool Karim et al. LANCET
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Emerging SARS-CoV-2 variants: shooting the messenger
- (2021) The Lancet Infectious Diseases LANCET INFECTIOUS DISEASES
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
- (2021) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface
- (2021) Khan Sharun et al. VACCINE
- Protective effects elicited by cow milk fermented with L. Paracasei CBAL74 against SARS-CoV-2 infection in human enterocytes
- (2021) Lorella Paparo et al. Journal of Functional Foods
- Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt
- (2021) Manish Dhawan et al. International Journal of Surgery
- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
- (2020) Daniel Wrapp et al. CELL
- Deployment of convalescent plasma for the prevention and treatment of COVID-19
- (2020) Evan M. Bloch et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models
- (2020) Casey C. Perley et al. Frontiers in Microbiology
- Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
- (2020) Khan Sharun et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
- (2020) Jiangdong Huo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries
- (2020) Evan M. Bloch et al. VOX SANGUINIS
- COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines
- (2020) Mohd. Iqbal Yatoo et al. Human Vaccines & Immunotherapeutics
- Finding Camel-ot: A Holy Grail against pandemic SARS-CoV-2?
- (2020) Deborah Soong et al. Science Immunology
- Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
- (2020) Eriko Padron-Regalado Infectious Diseases and Therapy
- Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain
- (2020) Rongyuan Gao et al. JOURNAL OF VIROLOGY
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
- (2020) Leo Hanke et al. Nature Communications
- Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
- (2020) Xiaojing Chi et al. Nature Communications
- Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
- (2020) Jianbo Dong et al. Scientific Reports
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
- (2020) Allison J. Greaney et al. Cell Host & Microbe
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 infection in farmed minks, associated zoonotic concerns, and importance of the One Health approach during the ongoing COVID-19 pandemic
- (2020) Khan Sharun et al. VETERINARY QUARTERLY
- High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
- (2020) Thomas J. Esparza et al. Scientific Reports
- Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters
- (2019) Venkatraman Siddharthan et al. Viruses-Basel
- Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
- (2019) Lei He et al. Viruses-Basel
- Nanobodies that Neutralize HIV
- (2019) Weiss et al. Vaccines
- A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
- (2018) Guangyu Zhao et al. JOURNAL OF VIROLOGY
- Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
- (2018) John H Beigel et al. LANCET INFECTIOUS DISEASES
- Selection and characterization of protective anti-chikungunya virus single domain antibodies
- (2018) Jinny L. Liu et al. MOLECULAR IMMUNOLOGY
- Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus
- (2017) Christina L. Gardner et al. JOURNAL OF VIROLOGY
- Nanobodies® † †Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases
- (2017) Gino Van Heeke et al. PHARMACOLOGY & THERAPEUTICS
- Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization
- (2017) Anna D. Koromyslova et al. PLoS Pathogens
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications
- (2016) Yongzhong Wang et al. International Journal of Nanomedicine
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
- (2016) Flora Peyvandi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
- (2016) Thomas Luke et al. Science Translational Medicine
- Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens
- (2016) Rashmi Dixit et al. VACCINE
- Anti-VP6 VHH: An Experimental Treatment for Rotavirus A-Associated Disease
- (2016) Lucía Maffey et al. PLoS One
- Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle
- (2016) John M. Dye et al. Scientific Reports
- Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
- (2015) Laurent Detalle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle
- (2015) Hiroaki Matsushita et al. PLoS One
- A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity
- (2014) Eline Boons et al. ANTIVIRAL RESEARCH
- Intracellular Expression of Camelid Single-Domain Antibodies Specific for Influenza Virus Nucleoprotein Uncovers Distinct Features of Its Nuclear Localization
- (2014) Joseph Ashour et al. JOURNAL OF VIROLOGY
- A general protocol for the generation of Nanobodies for structural biology
- (2014) Els Pardon et al. Nature Protocols
- Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis
- (2014) Aneela Fatima et al. PLoS One
- DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome
- (2014) J. W. Hooper et al. Science Translational Medicine
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission
- (2013) Alexander W. Tarr et al. HEPATOLOGY
- Cell Penetrable Humanized-VH/VHH That Inhibit RNA Dependent RNA Polymerase (NS5B) of HCV
- (2012) Kanyarat Thueng-in et al. PLoS One
- Nanobody; an Old Concept and New Vehicle for Immunotargeting
- (2011) Fatemeh Rahbarizadeh et al. IMMUNOLOGICAL INVESTIGATIONS
- Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion
- (2011) Bert Schepens et al. JOURNAL OF INFECTIOUS DISEASES
- Potent Neutralization of Influenza A Virus by a Single-Domain Antibody Blocking M2 Ion Channel Protein
- (2011) Guowei Wei et al. PLoS One
- In vitro antiviral activity of single domain antibody fragments against poliovirus
- (2010) Bert Thys et al. ANTIVIRAL RESEARCH
- Hark back: Passive immunotherapy for influenza and other serious infections
- (2010) Thomas C. Luke et al. CRITICAL CARE MEDICINE
- Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120
- (2008) A. Forsman et al. JOURNAL OF VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started